ARCB vs CTOS

ArcBest Corporation's Piotroski F-Score of 4/9 indicates weak financial health, signaling deterioration in operational efficiency and profitability. The absence of an Altman Z-Score raises concern about potential distress risk, especially given a current ratio of 0.95 and quick ratio of 0.79, both below safe thresholds. Despite a seemingly attractive forward P/E of 11.68, the company exhibits negative revenue growth (-2.90% YoY) and severe earnings declines (YoY EPS down 72.9%), undermining long-term sustainability. The Graham Number of $58.46 suggests a defensive fair value, yet the stock trades at $84.87—over 44% above this benchmark—indicating significant overvaluation. Analysts' 'buy' recommendation appears misaligned with deteriorating fundamentals.

CTOS exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health. While the stock has seen a massive 1-year price surge (+105.2%), this momentum is disconnected from the underlying financials, which show negative profit margins (-1.60%) and declining earnings growth (-26.50%). High leverage (Debt/Equity of 2.99) combined with a dangerously low Quick Ratio (0.24) suggests significant liquidity risk. The valuation is stretched with a Forward P/E of 41.62 despite stagnant revenue growth.